Drug Profile
JCAR 015
Alternative Names: anti-CD19-CD28-zeta CAR transduced T cells - Juno Therapeutics; anti-CD19-CD28-zeta modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; CD28-modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; JCAR 15; JCAR015Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Juno Therapeutics; Memorial Sloan-Kettering Cancer Center
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 31 May 2019 Efficacy and adverse events data from a phase I trial in Precursor B-cell lymphoblastic leukaemia lymphoma presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
- 06 Mar 2018 Juno Therapeutics has been acquired by Celgene